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Abstract
Aim: To determine how varenicline, bupropion, nicotine replacement therapy (NRT) and
electronic cigarettes compare with respect to their clinical effectiveness and safety.
Method: Systematic reviews and Bayesian network meta-analyses of randomized
controlled trials, in any setting, of varenicline, bupropion, NRT and e-cigarettes (in high,
standard and low doses, alone or in combination) in adult smokers and smokeless
tobacco users with follow-up duration of 24 weeks or greater (effectiveness) or any
duration (safety). Nine databases were searched until 19 February 2019. Primary
outcomes were sustained tobacco abstinence and serious adverse events (SAEs). We
estimated odds ratios (ORs) and treatment rankings and conducted meta-regression to
explore covariates.
Results: We identified 363 trials for effectiveness and 355 for safety. Most
monotherapies and combination therapies were more effective than placebo at helping
participants to achieve sustained abstinence; the most effective of these, estimated
with some imprecision, were varenicline standard [OR = 2.83, 95% credible interval (CrI)
= 2.34–3.39] and varenicline standard + NRT standard (OR = 5.75, 95% CrI = 2.27–
14.88). Estimates were higher in smokers receiving counselling than in those without
and in studies with higher baseline nicotine dependence scores than in those with lower
scores. Varenicline standard + NRT standard showed a high probability of being ranked
best or second-best. For safety, only bupropion at standard dose increased the odds of
experiencing SAEs compared with placebo (OR = 1.27, 95% CrI = 1.04–1.58), and we
found no evidence of effect modification.
Conclusions: Most tobacco cessation monotherapies and combination therapies are
more effective than placebo at helping participants to achieve sustained abstinence, with
varenicline appearing to be most effective based on current evidence. There does not
appear to be strong evidence of associations between most tobacco cessation
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pharmacotherapies and adverse events; however, the data are limited and there is a
need for improved reporting of safety data.
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INTRODUCTION
Cigarette smoking is a leading cause of premature mortality and
morbidity in the United Kingdom and world-wide [1,2], and repre-
sents a substantial economic burden. In 2012, the global amount of
health-care expenditure due to smoking-attributable diseases
totalled US$422 billion, while the global total economic cost of
smoking (from health expenditures and productivity losses together)
totalled US$1436 billion [3]. In the United Kingdom, three pharma-
cotherapies, varenicline, bupropion and nicotine replacement
therapy (NRT), are licensed by the Medicines and Healthcare prod-
ucts Regulatory Agency (MHRA) and recommended by the National
Institute for Health and Care Excellence (NICE) for smoking
cessation [4]. Although currently marketed electronic cigarettes
(e-cigarettes) are not licensed as tobacco cessation medicines, guid-
ance by NICE and Public Health England advise that they can be
considered for smokers who have been unable to quit using other
medicines and estimate that their use is 95% safer than smoking
conventional cigarettes [4–6]. However, in the United States,
e-cigarettes are not currently approved by the US Food and Drug
Administration (FDA) as a quit smoking aid, and to date no
electronic nicotine delivery systems (ENDS) products have been
authorized by the FDA [7]. Additionally, ENDS have been banned
in more than 30 countries [8].
It is essential that there is a clear understanding of the compara-
tive effectiveness of tobacco cessation pharmacotherapies and e-ciga-
rettes. However, there is a lack of clinical trials that compare tobacco
cessation pharmacotherapies against each other or in combination;
most trials estimate the effectiveness of these medicines as mono-
therapies against placebo. Additionally, given the popularity of e-
cigarette use in the United Kingdom (approximately 3.2 million adult
users in 2018) [9], it is important to review their effectiveness com-
pared with licensed tobacco cessation medicines.
Concerns have been raised previously regarding the safety of
tobacco cessation medicines, in particular varenicline, bupropion and
e-cigarettes. In July 2009, the FDA placed a Black Box warning
around a possible association with serious neuropsychiatric events
(i.e. depression, suicidal ideation and behaviour) on varenicline’s prod-
uct labelling [10]. This warning was removed in December 2016 [11],
mainly due to the findings of the Evaluating Adverse Events in a
Global Smoking Cessation Study (EAGLES) randomized controlled trial
(RCT) [12]. However, concerns about the validity of the EAGLES trial
have since been raised, as the study was only statistically powered to
detect a very large serious adverse effect; therefore, it would not have
been able to detect a rare adverse effect such as suicide [13]. Findings
from some studies suggested that the use of bupropion for smoking
cessation was associated with a greater risk of experiencing seizures
[14]. However, the most recent Cochrane Review of antidepressants
for smoking cessation [15] found insufficient evidence to conclusively
determine whether bupropion was associated with seizures as well as
other serious adverse events. Compared to placebo, findings from
previous reviews have suggested an increased risk of lower risk car-
diovascular disease events associated with the use of NRT [16], an
increased risk of nausea, insomnia, abnormal dreams, headache and
serious adverse events associated with the use of varenicline [17] and
an increased incidence of psychiatric adverse events such as anxiety
and insomnia associated with the use of bupropion [15]. Safety con-
cerns concerning e-cigarettes have been related to the risks of vari-
able manufacturing standards for the devices, risks associated with
flavouring components, the possibility of harmful constituents in e-
cigarettes and a lack of evidence regarding the long-term health
impact of e-cigarettes [18–20]. The 2019 US outbreak of e-cigarette
or vaping product use-associated lung injury resulted in approximately
3000 hospitalizations and 68 confirmed deaths. Vitamin E acetate in
illicit tetrahydrocannabinol (THC)-containing products has been
strongly implicated in this outbreak [21].
Network meta-analysis (NMA) is a method that enables compari-
son of any pair of interventions by pooling direct (head-to-head) and
indirect evidence from RCTs that form a network of intervention com-
parisons. NMA delivers the relative effect estimates needed to inform
policy and practice even if there is no direct evidence. The most
recent review of efficacy was an NMA conducted by the Irish Health
Information and Quality Authority (HIQA) [22], which updated data
from previous Cochrane Reviews [23] until August 2016. However,
since this date a number of new studies have reported, including stud-
ies of e-cigarettes. Reviews of safety have mainly focused upon com-
paring the safety of tobacco cessation medicines as monotherapies
with placebo [24–31], although comparisons with other active inter-
ventions are likely to be of greater clinical relevance to patients, pre-
scribers and regulatory agencies. As more trials report on the use of
combinations of tobacco cessation medicines, it is important for
reviews to include combined therapies. Additionally, previous safety
reviews of RCTs have excluded trials with fewer than 6 months of
follow-up, as they have focused upon including trials based on absti-
nence outcomes [17,32]. Therefore, many important adverse events
could have been missed.
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We aimed to perform comprehensive systematic reviews and
NMAs [33] of the effectiveness and safety of varenicline, bupropion,
NRT and e-cigarettes as monotherapies and combination therapies in
relation to each other, placebo, waiting-list, usual care or no drug
treatment to enable patients, prescribers and regulators to make
informed decisions regarding treatment choices.
METHODS
The protocol for this study is registered with the Prospective Regis-
ter of Systematic Reviews (PROSPERO) (CRD42016041302), and
has been published [34]. There were some protocol deviations. The
inclusion of electronic cigarettes and specification of covariates
were decided following the submission of our PROSPERO record
and protocol manuscript for peer review. The findings of our ana-
lyses of safety data from observational studies with control groups
[35] and our cost-effectiveness analyses [36] are reported else-
where. We were unable to include and analyse craving and with-
drawal data, as these were rarely reported among the included
studies and were measured using a variety of measures and scales,
so evidence synthesis was impossible. We made a pragmatic deci-
sion to only analyse biochemically verified data, as this is consid-
ered the recommended standard measure for cessation [37] and is
commonly used in reviews. We felt that this decision would retain
the most robust data and minimize bias and heterogeneity while
keeping the project manageable. Trials that only collected self-
reported data are included in the study characteristics and risk of
bias tables in the Supporting information Appendices of our Health
Technology Assessment (HTA) report [35]. We had planned to ana-
lyse sustained abstinence data from multiple follow-up times using
survival synthesis methods for time to relapse. However, we made
a pragmatic decision to analyse as a binary outcome at the 6-month
time-point.
Population
We included RCTs in any setting in adult smokers and smokeless
tobacco users with a follow-up duration of 24 weeks or greater (effec-
tiveness) or any duration (safety). We excluded studies in non-
smoking or non-smokeless tobacco-using populations and pregnant
and breastfeeding women.
Interventions
We included e-cigarettes and the three UK-licensed tobacco ces-
sation medicines (varenicline, bupropion and NRT) as monotherapies or
in combination. For NRT, combinations of different formulations given
concurrently (for example, patch and gum) were also included. We also
examined different dosages of treatments (see Table 1). Dosage cate-
gories were determined using the British National Formulary and the
MHRA public assessment report for the ‘e-Voke’, the first e-cigarette
to be licensed as a medicine but not currently marketed [38,39].
NRT treatments were classified as an NRT combination where
two or more NRT products were administered in combination in a sin-
gle arm and NRT choice, where participants were allowed to select
the NRT products they would use. The dosage for NRT combination
was indicated based on the highest dose among assigned products,
whereas dosage for NRT choice was only identified when a dose was
reported for every offered product. Trial arms where patients could
receive more than one intervention, but these were not defined
(unlike specified combination interventions), were excluded.
Eligible comparators were: other active interventions, placebo
(reference comparator for the NMA), no drug treatment, usual care
and waiting-list. ‘Placebo’ includes placebo tablet, NRT or electronic
cigarette with non-nicotine liquid. ‘No drug treatment’ was used
when participants were not given any medicine or placebo. ‘Usual
care’ was used as defined by the trial authors and did not include any
cessation medicines or placebo. Studies of counselling for tobacco
cessation were excluded unless one or more trial arms included a
tobacco cessation medicine or electronic cigarette.
T AB L E 1 Interventions by formulation and dosage.
Treatment (formulation) Low dose Standard dose High dose
Bupropion (oral extended-release tablets) < 150 mg bd 150 mg bd > 150 mg bd
Varenicline (tablets) < 1 mg bd 1 mg bd > 1 mg bd
E-cigarette (electronic inhaler, 5 cartridges/day) 10 mg 15 mg
Nicotine replacement therapy (NRT)
NRT patch (16 hours) < 15 mg 15 mg > 15 mg
NRT patch (24 hours) < 14 mg 14 mg > 14 mg
NRT gum (15/day) 2 mg 4 mg
NRT nasal spray (2 sprays/hour, 64/day) 0.5 mg
NRT mouth spray (4 sprays/hour, 64/day) 1 mg
NRT lozenge (1 lozenge/1–2 hours, 15/day) < 2 mg 2 mg 4 mg
NRT sublingual tablet (2 mg/tablet, 40/day) 1/hour 2/hour
NRT inhalator 10 mg (12/day) 15 mg (6/day)
NRT = nicotine replacement therapy; bd = twice daily.
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Search strategy and data extraction
We searched MEDLINE, Embase, PsycINFO, Web of Science,
clinicaltrials.gov and Cochrane Databases (Cochrane Database of Sys-
tematic Reviews, Database of Abstracts and Reviews of Effectiveness,
Cochrane Central Register of Controlled Trials) and the Health Tech-
nology Assessment Database with no language restrictions until
19 February 2019. The search strategy is included in the Supporting
information, Appendix, pp. 3–4. We also manually searched reference
lists of previous reviews.
At least two reviewers screened abstracts and identified full text
reports for inclusion using Covidence (covidence.org). Disagreements
were resolved by reaching consensus among reviewers. Data were
extracted by one reviewer onto electronic Microsoft Excel worksheets
and checked by co-reviewers. Study authors were contacted in the
event of missing data or unclear information. We assessed risk of bias
using the Cochrane risk of bias assessment tool for selection bias, per-
formance bias, detection bias, attrition bias, reporting bias and other
bias domains [40]. We created an ‘overall risk of bias’ as the highest
rating across all domains except the ‘selection bias’ domain, because




Only biochemically verified events were included. The primary effec-
tiveness outcome was sustained abstinence, defined as avoidance of
all tobacco use since the quit day until the time the assessment was
made, occasionally allowing for lapses. Secondary effectiveness out-
comes included prolonged abstinence (measure of cessation which
allows for a grace period following the quit date of up to 2 weeks),
any abstinence (abstinence by any definition at 6 months follow-up)
and 7-day point prevalence abstinence (PPA; measure of cessation
based on behaviour at a particular point in time) [41]. With the excep-
tion of any abstinence, outcome data from the longest reported time-
point were used.
Safety
The primary safety composite outcome was serious adverse events
(SAEs), defined as the number of participants experiencing events
that resulted in death, were life-threatening, required hospitalization
or resulted in significant disability [42]. Secondary safety composite
outcomes included major adverse cardiovascular events (MACEs),
including cardiovascular death, non-fatal myocardial infarction
(excluding unstable angina), fatal and non-fatal stroke [43], and major
adverse neuropsychiatric events (MANEs), comprising suicide,
attempted suicide, suicidal ideation, depression and seizures [26].
Adverse events were measured as the number of trial participants
experiencing an adverse event.
Data analysis
All outcomes were binary, extracted using the intention-to-treat prin-
ciple where participants missing from analyses were assumed to be
using tobacco (effectiveness) or not having experienced an adverse
event or SAE (safety). Where there were no events in at least one but
not all arms, we added 0.5 events to all cells in the 2 × 2 table for that
trial [44].
Random-effects NMAs were conducted within a Bayesian frame-
work using OpenBUGS (version 3.2.3). Studies comparing pharmaco-
logical treatment plus counselling versus counselling alone were
included and analysed as pharmacological treatment compared with
no drug treatment, under the assumption of no interaction when
pharmacological treatment and counselling are used together. Studies
comparing pharmacological treatment plus counselling versus usual
care were analysed as pharmacological treatment compared with no
drug treatment and the impact of the addition of counselling was esti-
mated using meta-regression. We ran a sensitivity analysis to exclude
such studies.
Heterogeneity was assessed by examining the between-study
standard deviation (SD) (τ) and 95% credible intervals (CrIs). We
fitted a standard (full interaction) NMA model as well as fixed and
random class NMA models for each outcome. Model fit was mea-
sured by the posterior mean residual deviance and models com-
pared using the deviance information criterion (DIC). Differences of
three or more were considered meaningful. The consistency
assumption was assessed by comparing model fit, DIC and variance
parameters for a model which relaxes consistency (unrelated mean
effects model) with the standard NMA model [45]. We also com-
pared direct and indirect estimates where both were available.
Results are presented as posterior median odds ratios (OR) and
95% CrIs. Although we report 95% CrIs we consider ‘statistical sig-
nificance levels’ to be a continuum [46], so the further the lower
credible limit is above 1 the stronger the evidence of effect, and
the width of credible intervals indicate levels of precision. We used
vague normal priors for all treatment effect parameters and uni-
form (0.5) priors for all standard deviation parameters. Full details
are reported in Thomas et al. [35] We also report the probability
that each intervention class is ranked best, second best, and so on,
across outcomes using rank-o-grams [33].
Meta-regression
We performed meta-regression [47] to explore the influence of
several pre-specified covariates: counselling, industry sponsorship,
treatment duration, baseline nicotine dependence score, com-
orbidities, willingness to quit, smokeless tobacco, smoking level and
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publication year. We performed sensitivity analyses excluding stud-
ies at high risk of bias for the primary outcomes (see Supporting
information, Appendix, p. 5). As an alternative to grading of recom-
mendations, assessment, development and evaluations (GRADE)
[48], a threshold analysis was performed for the primary outcomes
to assess the credibility of the results [49] and robustness of treat-
ment rankings to potential biases or uncertainty in the evidence
[48,50]. The method estimates thresholds which indicate how
much the evidence could change (for any reason, such as bias or
random error) before the treatment rankings or recommendations
change. By comparing the thresholds with judgements of the plau-
sible magnitude of potential biases and estimates of uncertainty
(confidence intervals) we can identify comparisons where conclu-
sions are robust and comparisons where conclusions are sensitive
to plausible biases or uncertainty in the evidence. We used thresh-
old analysis, as it makes explicit the links between the sources of
evidence, their quality and the treatment rankings by accounting
for the influence of evidence on the rankings, and is therefore
more directly applicable to treatment rankings and recommenda-
tions, whereas tools such as GRADE only consider the quality of
evidence [48,49].
Ethical approval
Ethical approval for this evidence synthesis was not required.
RESULTS
Full results are reported in Thomas et al. [35]. We screened 15 495
records and reviewed 2561 full text articles (Figure 1). The EAGLES
study [12] was treated as two separate studies for our analyses, Ant-
henelli 2016A from the non-psychiatric cohort and Anthenelli 2016B
from the psychiatric cohort.
Effectiveness
We included 363 trials from 361 articles with a total of 201 045 par-
ticipants (Supporting information, Appendix, pp. 6–21).
Trials were conducted across six continents with 208 US trials,
29 UK trials and 27 multi-centre international trials. The studies
ranged in duration from 6 months to 14.5 years, with duration of drug
F I GU R E 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram for effectiveness study records
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treatment from 2 weeks to 2 years. Trial participants included a mix
of ethnicities, with a mean age ranging from 27 to 62 years. The over-
all risk of bias for included studies was rated as 40% high, 47% unclear
and 13% low. A risk of bias assessment summary figure is available in
the Supporting information, Figure S1.
For all outcomes, model fit indices favoured fixed class
NMA models, and there was no evidence of inconsistency for this
model (Supporting information, Table S1). There was moderate
heterogeneity for all efficacy outcomes (Supporting information,
Tables S2–S9). Of the included trials, 252 trials contributed to at
least one NMA for effectiveness outcomes. Fifty-one trials were
not included in analyses because they did not report any biochemi-
cally verified outcomes.
Sustained abstinence
A total of 171 studies (90 443 participants) reported on sustained
abstinence at a follow-up of at least 24 weeks, of which 161 (86 884
participants) compared two or more of the intervention classes of
interest (Figure 2a).
ORs for sustained abstinence are reported in Figure 3a (see also
Supporting information, Table S2). Most interventions were more
effective than placebo, although some estimates were extremely
imprecise. For interventions estimated with some precision there was
evidence that smokers receiving varenicline standard (OR = 2.83, 95%
CrI = 2.34–3.39), NRT high (OR = 2.32, 95% CrI = 1.88–2.86), NRT
standard (OR = 2.01, 95% CrI = 1.68–2.41), varenicline low
(OR = 1.79, 95% CrI = 1.07–2.97), bupropion low (OR = 1.75, 95%
CrI = 1.03–3.00) and bupropion standard (OR = 1.73, 95% CrI = 1.43–
2.10) were more likely to quit relative to placebo. There was evidence
that varenicline standard + NRT standard (OR = 5.75, 95% CrI = 2.27–
14.88), varenicline low + NRT standard (OR = 5.70, 95% CrI = 1.57–
21.12), varenicline standard + bupropion standard (OR = 3.25, 95%
CrI = 1.35–7.92), e-cigarette high (OR = 3.22, 95% CrI = 1.63–6.36)
and varenicline standard + NRT high (OR = 2.34, 95% CrI = 1.12–
4.90) were effective relative to placebo, but these estimates are
extremely imprecise. There was an indication that e-cigarette low may
be more effective than placebo (OR = 3.22, 95% CrI = 0.97–12.55);
however, this estimate is extremely imprecise, and the CrIs also incor-
porate the possibility of no effect.
Most effect estimates from pairwise comparisons between inter-
ventions for sustained abstinence were informed by indirect evidence
only, and results were consistent when both direct and indirect evi-
dence were available (Supporting information, Table S3). There was
evidence that smokers randomized to varenicline standard + NRT
F I GU R E 2 Network meta-analysis of eligible comparisons for sustained abstinence (a), prolonged abstinence (b), any abstinence (c) and 7-day
point prevalence abstinence (PPA) (d). Thicker edges in network figures represent comparisons with a higher number of randomized patients,
while interventions with a larger number of randomized patients have larger circles. Interventions were excluded if they were disconnected from
the main network
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standard were more likely to achieve sustained abstinence than those
receiving NRT standard (OR = 2.87, 95% CrI = 1.11–7.49) or
bupropion standard (OR = 3.34, 95% CrI = 1.28–8.65). Results also
suggest higher odds of abstinence for varenicline standard versus
NRT standard (OR = 1.40, 95% CrI = 1.10–1.78) and bupropion stan-
dard (OR = 1.63, 95% CrI = 1.27–2.07).
Meta-regression results
There was evidence of effect modification as a function of counsel-
ling, with interventions that included counselling being associated
with higher ORs for achieving sustained abstinence (ratio of
ORs = 2.36, 95% CrI = 1.57–3.56). We also found a higher OR of
sustained abstinence among participants with higher average base-
line nicotine dependence scores (ORs ratio = 1.26, 95% CrI = 1.02–
1.54). We found no evidence of effect modification for any other
covariates. Excluding studies at high risk of bias yielded similar find-
ings, although with wider intervals for most effect estimates, partic-
ularly for e-cigarettes and treatment combinations. The threshold
analysis (Supporting information, Appendix, pp. 27–28) shows that
our finding that varenicline standard + NRT standard has the highest
estimated odds ratio (OR = 5.75, 95% CrI = 2.27–14.88) is robust,
but sensitive to the level of imprecision and potential biases in five
studies (three rated high or unclear risk of bias), which could lead to
either varenicline + bupropion standard , e-cigarette low or e-
F I GU R E 3 Forest plot with results of the fixed class network meta-analysis (NMA) model for sustained abstinence (a), prolonged abstinence
(b), any abstinence (c) and 7-day point prevalence abstinence (PPA) (d)
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cigarette high being ranked first for sustained abstinence. However,
any possible biases in low/unclear risk of bias-rated studies would
have to alter the OR by at least a factor of 1.6 to change the first-
place ranking.
Prolonged, any abstinence and 7-day PPA
Similar results to those for sustained abstinence were obtained for
the other abstinence outcomes (Supporting information, Appendix,
pp. 29–35). Relative to placebo, smokers treated with standard
doses of varenicline (OR = 3.63, 95% CrI = 2.23–6.36) and
bupropion (OR = 2.34, 95% CrI = 1.46–3.86) as monotherapies and
in combination (OR = 4.76, 95% CrI = 2.48–10.10) were more likely
to achieve prolonged abstinence (Figure 3b). There were no avail-
able data for combined varenicline and NRT at standard doses for
this outcome.
For the any abstinence outcome (Figure 3c), standard varenicline
was more effective than standard doses of NRT (OR = 1.32, 95%
CrI = 1.05–1.65) and bupropion (OR = 1.46, 95% CrI = 1.18–1.81).
Combined varenicline and NRT at standard doses was also more
effective than standard doses of NRT (OR = 2.70, 95% CrI = 1.02 to
F I GU R E 4 Rank-o-gram of intervention classes (at standard doses with the exception of e-cigarettes) across effectiveness outcomes. All nine
intervention classes contributed to the ranking for any abstinence, whereas eight intervention classes were included for sustained abstinence
[bupropion standard + nicotine replacement therapy (NRT) had no data], six for 7-day point prevalence abstinence (PPA) (e-cigarette low, e-
cigarette high and bupropion standard + NRT standard had no data) and four for prolonged abstinence (no data for NRT standard, e-cigarette low,
e-cigarette high, bupropion standard + NRT standard, varenicline standard + NRT standard)
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7.13) and bupropion (OR = 2.99, 95% CrI = 1.13–7.88). These findings
were also observed for the 7-day point prevalence abstinence out-
come (Figure 3d).
Varenicline standard + NRT standard showed a high probability
to be ranked best or second-best intervention for three outcomes
(although there was no information available for this drug combination
on prolonged abstinence) (Figure 4). Varenicline standard + bupropion
standard yielded the highest probability to be ranked as the best inter-
vention for prolonged abstinence, although there was higher uncer-
tainty concerning its ranking for the other outcomes. Varenicline
standard showed the highest probabilities to be ranked second- to
fourth-best for the different outcomes, whereas e-cigarettes pres-
ented a more uncertain ranking profile. Placebo was ranked as the
least effective option for all outcomes. The findings for the standard
doses also held in the rank-o-grams across all doses (Supporting infor-
mation, Figure S3).
As an indication of absolute effects, sustained abstinence proba-
bilities are given for a UK population by applying the odds ratios from
the NMA to the probability of 1-year continuous cessation based on
NRT standard taken from Taylor et al. [51] (Supporting information,
Table S10).
Safety
We included 355 trials from 353 articles with a total of 159 101
participants (Supporting information, Appendix, pp. 39–51)
(Figure 5).
Trials were conducted across six continents, with 211 US trials,
34 UK trials and 31 multi-centre international trials. Trial duration
ranged from 1 day/single session to 14.5 years, and duration of drug
treatment ranged from half a day to 2 years.
Trial participants included a mix of ethnicities, with a mean age
ranging from 28.4 to 62.8 years. The overall risk of bias for included
trials was rated as 33% high, 51% unclear and 16% low. A risk of
bias summary figure is available in the Supporting information,
Figure S4.
For all outcomes, model fit indices favoured fixed-class NMA
models, and there was no evidence of inconsistency for this model
(Supporting information, Table S11). There was very little heteroge-
neity for SAE, but moderate heterogeneity for other safety out-
comes (Supporting information, Tables S12–S17). Of the included
trials, 149 trials contributed to at least one NMA for safety
outcomes.
F I GU R E 5 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram for safety study records
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SAEs
A total of 111 trials reported on SAEs with a total of 63 927 patients,
of which 101 (58 318 patients) compared two or more of the treat-
ment classes of interest (Figure 6a). We excluded one study [52] from
all analyses due to small event numbers causing computational
problems.
Figure 7a (and Supporting information, Table S12) displays the
class-level NMA results for each intervention relative to placebo.
There was evidence that bupropion standard (OR = 1.27, 95%
CrI = 1.04–1.58) increased the odds of SAEs compared to placebo.
The 95% CrIs for all other treatments compared with placebo crossed
1 (no effect).
Most effect estimates for comparisons between active interven-
tions were informed by indirect evidence only (Supporting informa-
tion, Table S13). As a consequence of this, and also due to the small
event rates reported, effects were imprecisely estimated and all 95%
CrIs contained 1 (no effect).
Meta-regression results
There was no evidence of effect modification for any factors explored.
Excluding trials at high risk of bias yielded similar results, although
with wider intervals for most effect estimates [35]. The threshold ana-
lyses show that the best- and worst-ranked treatments are sensitive
to uncertainty and potential biases in the data (Supporting informa-
tion, Appendix, pp. 56–57), indicating that we cannot draw robust
conclusions from these data.
MACEs
A total of 49 trials (38 329 patients) reported MACEs, with 44 trials
(36 231 patients) including at least one relevant comparison
(Figure 6b). We discarded three trials [52–54] from all analyses due to
small numbers causing computational problems.
Due to the small numbers of events reported across trials, all
effect estimates show very wide intervals and hence it was not
possible to reliably estimate differences in comparison to placebo
(Figure 7b, Supporting information, Table S14) or between pairs of
interventions (Supporting information, Table S15).
MANEs
MANEs were reported in 75 trials (42 088 patients), with 73 trials
(41 483 patients) including at least one relevant comparison. Placebo,
NRT not specified, bupropion standard and varenicline standard were
the best-represented interventions (Figure 6c). We excluded two trials
F I GU R E 6 Network meta-analysis of eligible comparisons for serious adverse events (a), major adverse cardiovascular events (b) and major
adverse neuropsychiatric events (c). Thicker edges in network figures represent comparisons with a higher number of randomized patients, while
interventions with a larger number of randomized patients have larger circles
10 THOMAS ET AL.
[55,56] from all analyses due to small numbers causing computational
problems.
The class-level NMA results for MANEs for each intervention
class relative to placebo are presented in Figure 7c (and Supporting
information, Table S16) and show wide intervals around the effect
estimates due to small numbers. There was evidence that smokers
randomized to waiting-list (OR = 0.03, 95% CrI = 0.00–0.44),
bupropion standard + NRT high (OR = 0.21, 95% CrI = 0.03–0.92),
NRT not specified (OR = 0.60, 95% CrI = 0.36–0.89) and bupropion
standard (OR = 0.67, 95% CrI = 0.47–0.91) were less likely to report
MANEs compared to placebo.
Although most effect estimates were imprecisely estimated
due to small numbers, there was evidence of an increased odds of
MANEs for smokers randomized to varenicline standard compared
to those allocated to bupropion standard (OR = 1.43, 95%
CrI = 1.02–2.09) (Supporting information, Table S17).
Placebo was most likely to be ranked best or second-best out of
nine interventions for SAEs, but ranked in the middle for MACEs and
MANEs (Figure 8). NRT standard was also most likely to be ranked
among the best two interventions to reduce the odds of SAEs, with
uncertain rankings for the other adverse outcomes. Note, however,
that all these rankings are based on imprecise effect estimates and
may not be robust.
As an indication of absolute effects, the average proportion of
patients with an event in the placebo arm across trials for safety out-
comes are given in the Supporting information, Table S18.
DISCUSSION
To our knowledge, this is the largest NMA to examine the effective-
ness and safety of tobacco cessation pharmacotherapies and e-ciga-
rettes, and the first NMA with respect to SAE and MANEs.
Principal findings
Effectiveness
Most monotherapies and combination therapies were more effective
than placebo at helping participants to achieve sustained abstinence.
Compared to placebo, the most effective therapy that was estimated
with some precision was varenicline standard. Varenicline standard
+ NRT standard, varenicline low + NRT standard, e-cigarette high and
e-cigarette low show potential to be effective; however, the estimates
are extremely imprecise. Smokers randomized to a combination of
varenicline and NRT at standard doses were also more likely to
achieve sustained abstinence than participants receiving standard
NRT or bupropion as monotherapies. Standard doses of varenicline
were more effective than standard doses of NRT or bupropion mono-
therapies. There was evidence that interventions delivered with
counselling were more effective than the same interventions deliv-
ered without counselling, and effects were greater in studies on par-
ticipants with higher baseline nicotine dependence scores.
Similar results to those for sustained abstinence were obtained
for the other abstinence outcomes. Among almost all outcomes, com-
bined varenicline and NRT at standard doses had the highest probabil-
ity of being ranked as the best or second-best, e-cigarette rankings
were uncertain and placebo consistently ranked last.
Safety
While the use of bupropion standard may increase the odds of
SAEs compared to placebo, we did not find strong evidence of any
other negative associations between tobacco cessation medicines
and SAEs, MACEs or MANEs relative to placebo. In pairwise com-
parisons between interventions there was evidence of an increased
odds of MANEs for smokers randomized to varenicline standard
F I GU R E 7 Forest plot with results of the fixed-class network meta-analysis (NMA) model for serious adverse events (a), major adverse
cardiovascular events (b) and major adverse neuropsychiatric events (c)
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compared to those using bupropion standard. When ranking the
interventions among primary and secondary safety outcomes, pla-
cebo and NRT standard were most likely to be ranked among the
best interventions for reducing the odds of experiencing SAEs, but
were ranked lower for MACEs and MANEs. The safety profile of
e-cigarettes was uncertain.
Strengths and weaknesses
One of the most significant strengths of this study is the inclusion of
combinations of tobacco cessation pharmacotherapies, whereas
previous analyses examined only monotherapies or combination NRT.
This is also the first NMA to compare medicines stratified by dosage,
which allowed more specific identification of the impact of dose
across different outcomes and avoided heterogeneity. We were also
able to include recent large trials, such as the e-cigarette trial by Hajek
et al. [56]. A further strength is the methodology employed, con-
ducting NMAs for multiple cessation outcomes in addition to using
the most rigorous definition of abstinence (biochemically verified
sustained abstinence). The size of the study also allowed investigation
of several important covariates as potential effect modifiers. For
safety, our decision to include RCTs of any duration ensured that we
maximized the use of available data.
F I GU R E 8 Rank-o-gram of interventions across safety outcomes. Eight intervention classes contributed to the ranking for serious adverse
events [bupropion standard + nicotine standard replacement therapy (NRT) had no data], whereas six intervention classes were included for
major adverse neuropsychiatric events (e-cigarette low, e-cigarette high and bupropion standard + NRT standard had no data) and seven for
major adverse cardiovascular events (e-cigarette low and varenicline standard + NRT standard had no data)
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There are several important limitations of this study. Our
searches used to retrieve publications are more than 2 years old, so
our study may not include more recent findings, especially with
respect to e-cigarettes, where several trials were ongoing and some
have since been published. However, this study remains the largest
network meta-analysis of tobacco cessation medicines to date.
Despite the large number of studies included data limitations
remained, such that comparisons between active interventions were
almost exclusively informed by indirect evidence, resulting in impre-
cisely estimated effects and wide confidence intervals which
included the null value. While stratifying by dose was a strength of
our study, this has contributed to some imprecision in the results.
Additionally, in some instances extreme results were obtained based
on the findings of a single or very few trials, which may be particu-
larly problematic when attempting to draw conclusions regarding
the safety of e-cigarettes. We used the longest follow-up time
reported, which varied between studies and could have introduced
heterogeneity. A small number of studies were cluster-randomized;
however, intracluster correlations were not available and we were
unable to adjust for clustering, which would give slightly less precise
estimates. A large proportion of studies were rated as being at high
or uncertain risk of bias, as many studies were at risk of selective
reporting or did not adequately report random sequence generation
and allocation concealment. Although we endeavoured to obtain
unpublished data and contacted study authors for additional mate-
rial, we are aware that data may still be missing from our analyses.
Despite extensive efforts we were unable to obtain safety data for
industry-funded trials from pharmaceutical companies, and our find-
ings are limited to those events reported in published articles.
Safety outcomes included rare events, which limited the ability of
analyses to draw firm conclusions. Additionally, we excluded preg-
nant or breastfeeding women from this study, as not all the
included interventions are licensed for use in this population. How-
ever, we acknowledge that this is an important and understudied
population with a critical need of support to stop using tobacco
[57]. We made an assumption that the effect of counselling is addi-
tive when given together with a pharmacotherapy, which is a
potential limitation of our findings. It may be that there is a syner-
gistic (or even antagonistic) effect of counselling when used
together with pharmacotherapies. We explored this in a sensitivity
analysis and found that there was some evidence to support a syn-
ergistic effect [35]. Future research to explore this potential syner-
gistic effect of smoking cessation medicines being used together
with counselling would be of value. Finally, we acknowledge the
decision to only analyse biochemically verified cessation data as a
study limitation, as this ultimately decreased the number of studies
and the amount of data included in our analyses, and we recognize
that a lack of biochemical verification should not be used as an indi-
cator of study quality. The use of biochemical verification is imprac-
tical for several study designs, has drawbacks and self-reported
cessation is often considered adequate in the absence of special cir-
cumstances [37].
Comparison to other studies
Our findings are largely comparable to those of previous NMAs
[22,23]. We found evidence that nearly all identified doses of tobacco
cessation medicines increased the probability of sustained abstinence
compared to placebo. For combined bupropion + NRT, although the
HIQA report [22] found evidence that this treatment improved the
likelihood of cessation (from the quit date or PPA) compared to pla-
cebo (control), this was only observed in our analyses for ‘any absti-
nence’ and 7-day PPA outcomes, and not for sustained or prolonged
outcomes. Similar to our findings, previous NMAs also found evidence
that monotherapy with varenicline increased the chance of cessation
compared to bupropion and to NRT, while finding inconclusive evi-
dence of a difference in likelihood of quitting between bupropion and
NRT [22,23]. Findings were also consistent for combined varenicline
+ NRT, which showed improved probability of quitting compared to
bupropion and NRT monotherapies. Although the HIQA report
showed that combined varenicline and bupropion was more effective
than bupropion or NRT delivered as monotherapies, we did not [22].
However, we stratified our analyses by dose, while theirs did not. The
results of ranking of tobacco cessation treatments were similar
throughout NMAs [22,23]. Our results were also comparable to those
of the latest relevant Cochrane Systematic Reviews: we similarly
found very imprecise evidence that e-cigarettes led to higher quit
rates than placebo and NRT [58], that varenicline was more effective
for achieving sustained abstinence than placebo (at low and standard
doses), bupropion and NRT [17], that bupropion standard increased
sustained abstinence compared to placebo [15] and that various forms
of NRT were more effective than placebo at standard and high
doses [32].
Two previous NMAs [22,23] only narratively summarized safety
data from previous systematic reviews without further analysis. Unlike
some previous reviews [22,58] we included all SAEs, regardless of
whether or not study authors attributed them to intervention use,
resulting in the inclusion of an additional study of electronic cigarettes
[59] for our SAE outcome analyses. The findings of our NMA of
MACEs mirrors that of Mills and colleagues [16], who also found no
evidence of any tobacco cessation treatment increasing the likelihood
of experiencing a MACE compared to placebo or each other. As
pairwise comparisons between active interventions were almost
entirely based on indirect evidence only and because MACEs were
uncommon, it was extremely difficult to effectively compare treat-
ments to each other. Compared to a recent Cochrane Review [17], we
did not find strong evidence that varenicline increased the chance of
experiencing SAEs relative to placebo, but we found evidence of an
increased odds of MANEs for smokers randomized to varenicline
standard compared to bupropion standard. In contrast to a recent
review [15], we found evidence that bupropion standard increased
the odds of serious adverse events compared to placebo. However,
we stratified analyses by dose while the review did not, and it
included no pharmacotherapy controls in addition to placebo as
comparators.
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Conclusions and future research
Regardless of the aforementioned limitations, this study strengthens
the evidence base for the use of varenicline and NRT mono-
therapies as first-line choices for tobacco cessation, in line with cur-
rent NICE recommendations [4], and should provide some
reassurance to patients, clinicians and policymakers regarding the
safety of most of these treatments. While bupropion was effective,
it was associated with increased odds of experiencing a SAE.
Although e-cigarettes showed promise as cessation tools, more
research is needed on their long-term effectiveness and safety, pref-
erably in studies with active interventions as comparators. Our find-
ings also suggest an important role for the use of combination
tobacco cessation therapies (for example, varenicline and NRT),
which may offer smokers a better chance of successfully quitting
tobacco over short and long time-periods. Although combination
NRT is commonly prescribed, the other drug combinations are
sometimes not licensed. While not the focus of this paper, we found
that combining counselling and pharmacological treatments
increased cessation rates compared to pharmacological treatment
alone. Further research to explore the effectiveness of combination
pharmacological treatment and counselling or psychological interven-
tions is likely to be of value. Researchers should ensure comprehen-
sive reporting of safety data in trials to ensure completeness of
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